Clinical Trials
23 trialsNCT05669664 2026-05-13
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00939627 2026-03-10
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
Phase 2 Completed
NCT01175980 2020-08-03
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01604772 2019-05-01
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00859937 2018-04-20
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00095563 2017-04-18
Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
National Cancer Institute (NCI)
Phase 2 Completed
NCT01256385 2017-03-27
MAESTRO HN
National Cancer Institute (NCI)
Phase 2 Completed
NCT00095628 2017-03-06
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00458978 2015-05-05
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00114283 2015-04-15
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00507767 2014-10-01
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00492089 2014-05-09
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003856 2013-12-19
Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00022217 2013-12-18
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00637637 2013-08-12
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00019331 2013-06-20
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00020189 2013-06-19
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00062387 2013-06-03
Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00096512 2013-02-28
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00126607 2013-02-28
Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00033618 2013-02-27
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
Phase 2 Completed
NCT00077428 2013-01-24
Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck
National Cancer Institute (NCI)
Phase 2 Completed
NCT00738868 2011-05-13
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed